Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) Consolidated Net Income (2018 - 2026)

10x Genomics' Consolidated Net Income history spans 8 years, with the latest figure at -$16.3 million for Q4 2025.

  • On a quarterly basis, Consolidated Net Income rose 66.85% to -$16.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$43.5 million, a 76.16% increase, with the full-year FY2025 number at -$43.5 million, up 76.16% from a year prior.
  • Consolidated Net Income hit -$16.3 million in Q4 2025 for 10x Genomics, up from -$27.5 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for TXG hit a ceiling of $34.5 million in Q2 2025 and a floor of -$93.0 million in Q3 2023.
  • Historically, Consolidated Net Income has averaged -$35.3 million across 5 years, with a median of -$36.8 million in 2024.
  • Biggest five-year swings in Consolidated Net Income: plummeted 483.22% in 2022 and later skyrocketed 191.14% in 2025.
  • Tracing TXG's Consolidated Net Income over 5 years: stood at -$18.4 million in 2021, then increased by 6.69% to -$17.2 million in 2022, then plummeted by 184.36% to -$49.0 million in 2023, then decreased by 0.16% to -$49.0 million in 2024, then soared by 66.85% to -$16.3 million in 2025.
  • Business Quant data shows Consolidated Net Income for TXG at -$16.3 million in Q4 2025, -$27.5 million in Q3 2025, and $34.5 million in Q2 2025.